By proceeding, you agree to our Terms of Use and Privacy Policy.
In vivo gene engineering is fast becoming known as the future of cell and gene therapy with incredible amounts of investment seen in 2021, including the recent Moderna and Metagenomi collaboration alongside the partnership between Abintus Bio and MSKCC, and Tidal acquisition by Sanofi.
Learn from industry pioneers, from Sana Biotechnology, Umoja Biopharma, Beam Therapeutics and Capstan Therapeutics.
Unite with the greatest minds in-person, this July, to ensure your pipeline remains at the forefront of innovative drug development.
Get enlightened with sessions like Pioneering the In Vivo cell engineering approach, a regulatory perspective: implications for the In Vivo Approach, etc.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Hanson Wade specialises in bringing people together through outstanding business conferences and year round community contact. We accelerate growth across industry and across the globe.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.